ICICI Securities has maintained its HOLD rating on Torrent Pharma, nudging up its 12-month target price to Rs 4,800 from Rs 4,600 earlier — a modest 4% upside from the current market price of Rs 4,620. The brokerage's report, dated July 1, 2026, credits the revision to stronger-than-expected traction across Torrent's India and Brazil operations, alongside the company's expanding footprint in the fast-growing GLP-1 (weight-loss and diabetes) drug category. Below is a breakdown of the key drivers, risks and valuation math behind the call.

A Diabetes Giant Doubling Down on GLP-1

Torrent has quietly assembled one of India's most diversified generic GLP-1 portfolios, commanding an estimated 34–35% volume market share in the country's generic semaglutide space, according to IQVIA data cited in the report. The company has partnered with Zydus for reusable-pen delivery under the Sembolic brand and with Dr. Reddy's for single-use pens marketed as Semalix — while also becoming the first Indian firm to roll out an oral solid-dose version of semaglutide. Management is targeting Rs 2–2.5 billion in GLP-1 sales for fiscal 2027.

Pricing Power Remains the Secret Weapon

Roughly 75–77% of Torrent's India revenue flows from chronic therapies, a segment where limited exposure to price-controlled essential medicines has let the company push through annual price hikes of 6–7%. Analysts expect India growth to outstrip the broader Indian Pharmaceutical Market's 10–12% pace by another 250–400 basis points, aided by a field force of 7,100 medical representatives — set to grow by 300 to 400 more recruits in FY27.

JB Pharma Merger Nears the Finish Line

The long-awaited merger with JB Pharma is expected to close by July 2026, pending NCLT approval. The tie-up is projected to deliver Rs 4–4.5 billion in cost synergies over three years while catapulting Torrent to the 5th-largest pharmaceutical company in India by IPM ranking. JB Pharma brings a 2,600-strong MR team and reinforces Torrent's standing in cardiology, gastrointestinal and ophthalmology segments — though the deal has also swelled the balance sheet considerably.

Brazil: The International Growth Engine

Latin America's largest economy remains Torrent's brightest overseas spot, with sales outpacing the local market — 17% growth versus a 6% market average. The company has 58 products awaiting ANVISA clearance and aims to double its therapeutic offerings in cardiovascular, diabetes and CNS categories over the next two to three years. A semaglutide launch is anticipated in Brazil next year, tapping into a USD 1 billion GLP-1 market currently dominated by Novo Nordisk's Wegovy, though price erosion of 30–40% looms as competition intensifies.

Mixed Signals from the US and Germany

The US business is climbing back after regulatory clearances at the Dahej and Indrad manufacturing plants, with 6–7 complex product launches planned annually and single-digit growth expected in FY27. Germany, however, remains a soft spot: supply-chain constraints have dented the sales run-rate, and management concedes a full recovery could take 12 to 18 months, though the recent launch of Torrent's first biosimilar there offers a silver lining.

The Numbers That Matter

ICICI Securities projects revenue, EBITDA and adjusted profit to compound at 26.6%, 27.8% and 24.9%, respectively, between FY26 and FY28, with margins expanding by roughly 63 basis points over that window. The stock's revised target is anchored to 25x FY28E EV/EBITDA, up from 24x previously.

Risks Cutting Both Ways

On the upside, faster-than-expected synergy realization from the JB Pharma deal, quicker debt paydown, and firmer pricing power in India could all push earnings ahead of estimates. Conversely, tighter price controls on more products, manufacturing or regulatory setbacks at plants, and adverse currency swings — particularly given Torrent's Brazil and international exposure — represent the principal downside risks flagged in the report.

Investor Takeaway: Levels to Watch

For investors tracking Torrent Pharma, the current market price of Rs 4,620 sits against a 52-week range of Rs 3,287 to Rs 4,743, meaning the stock is trading near its yearly highs. With the revised target of Rs 4,800, ICICI Securities' HOLD stance signals limited near-term upside rather than a fresh buying trigger — this is a "stay put, don't chase" call rather than an aggressive entry point. Existing holders may find comfort in the earnings trajectory and margin expansion story, while prospective buyers might prefer to await a more attractive entry level given the stock's rich valuation multiples of 64.7x FY27E and 48.9x FY28E earnings.